Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy.

Abstract

Respiratory viral infections in infants and young children frequently cause illness that can easily progress to hospitalization and death. There are currently no licensed vaccines to prevent respiratory viral disease in children younger than 6 months, reflecting safety concerns and the difficulty in inducing effective immune responses in infants. This review discusses vaccines that have been developed, or are currently being developed, against influenza and respiratory syncytial virus, with a focus on studies performed to demonstrate their safety and efficacy, and the impact of immunologic immaturity and maternal antibodies on the infant response to vaccines.

• Authors: Judy A Beeler, Maryna C Eichelberger
• Journal: Microbial pathogenesis (Microb Pathog) Vol. 55 Pg. 9-15 (Feb 2013) ISSN: 1096-1208 [Electronic] England
• PMID: 23247146 (Publication Type: Journal Article, Review)
• Copyright: Published by Elsevier Ltd.

Chemical References

• Influenza Vaccines
• Respiratory Syncytial Virus Vaccines

Topics

• Animals
• Humans
• Infant
• Influenza Vaccines (administration & dosage, adverse effects, immunology)
• Influenza, Human (immunology, prevention & control, virology)
• Orthomyxoviridae (immunology)
• Respiratory Syncytial Virus Infections (immunology, prevention & control, virology)
• Respiratory Syncytial Virus Vaccines (administration & dosage, adverse effects, immunology)
• Respiratory Syncytial Virus, Human (immunology)